Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?

To: tommysdad who wrote (1545)	3/15/2000 1:31:00 AM
From: scaram(o)uche	Read Replies (2) \| Respond to of 4974

Heh, heh. You're right up there with me when it comes to picking the correct day for this sort of stuff. Good news, I agree. I don't know enough about the target other than to say that the PR reads quite nicely. Will wait for Biotech Jim or Neuroinvest or ??? to bring us up to speed on GnRH antagonists. You know this molecule?

To: tommysdad who wrote (1545)	3/15/2000 8:01:00 AM
From: scott_jiminez	Respond to of 4974

A postdoc in the lab where I did my graduate work studied GnRH. His research-in-progress presentations were always 'interesting' since the graphic discussion of manipulating XX physiology was either extremely amusing or extremely disgusting. No middle ground. In any event, he is a co-author on this abstract ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7852501&dopt=Abstract which indicates that Dr. Vale and friends must keep in mind the direct effects of GnRH at sites outside the hypothalamic/pituitary/gonad axis. I'm unfamiliar with much of the work in this field so I don't know if 'non-axis' effects are significant or, more importantly, well understood.